PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$77.92
as of November 28, 2023 -
YTD RETURNS1.99%
as of November 28, 2023 -
Total Net Assets$377.01M
as of November 28, 2023 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Fund Description
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Overview
Fund Highlights
- Highly Liquid Companies
Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
- Industry Leaders
Index methodology favors the largest companies in the industry
- Global Scope
Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
RECOMMENDED INSIGHTS
Big Pharma's Billion-Dollar Weight Loss Drug Market
Big Pharma's Billion-Dollar Weight Loss Drug Market